Analyst Ratings for [ALLK] Allakos Inc.

1/17/24	Downgrades	Buy Hold	X
ALLK Allakos Jefferies
$6 $1.50
1/16/24	Downgrades	Overweight Neutral	X
ALLK Allakos Cantor Fitzgerald
12/18/23	Upgrades	Mkt Perform Outperform	X
ALLK Allakos William Blair
12/8/23	Resumed	Buy	X
ALLK Allakos Jefferies
$9 $6
9/27/23	Initiated	Mkt Outperform	X
ALLK Allakos JMP Securities
$11
5/12/23	Upgrades	Hold Buy	X
ALLK Allakos Jefferies
$6 $9
3/7/23	Initiated	Overweight	X
ALLK Allakos Piper Sandler
$22
9/12/22	Downgrades	Neutral Underperform	X
ALLK Allakos SMBC Nikko
$2
12/22/21	Downgrades	Outperform Mkt Perform	X
ALLK Allakos Cowen
12/22/21	Downgrades	Buy Hold	X
ALLK Allakos Jefferies
12/22/21	Downgrades	Outperform Mkt Perform	X
ALLK Allakos SVB Leerink
$17
12/22/21	Downgrades	Outperform Mkt Perform	X
ALLK Allakos William Blair
7/15/21	Initiated	Outperform	X
ALLK Allakos Cowen
5/18/21	Initiated	Buy	X
ALLK Allakos H.C. Wainwright
$230
2/24/21	Initiated	Overweight	X
ALLK Allakos Cantor Fitzgerald
$218
1/15/21	Initiated	Buy	X
ALLK Allakos BofA Securities
$145
8/13/18	Initiated	Neutral	X
ALLK Allakos Goldman
$31
8/13/18	Initiated	Buy	X
ALLK Allakos Jefferies
$53
8/13/18	Initiated	Outperform	X
ALLK Allakos William Blair

ALLK Allakos Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.